Broad-spectrum and virus-specific nucleic acid-based antivirals against influenza

Frontiers in Bioscience - Scholar

Volumn 2 S, Issue 2, 2010, Pages 791-800

  Wong, Jonathan P ^a   Christopher, Mary E ^a   Salazar, Andres M ^b   Sun, Lun Quan ^c   Viswanathan, Satya ^a   Wang, Ming ^c   Saravolac, Edward G ^d   Cairns, Murray J ^e  

^a DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

^b Washington   (United States)

^c CHINA AGRICULTURAL UNIVERSITY   (China)

^d Biotechnology Australia   (Australia)

^e UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Antisense; Antiviral; Catalytic; Gene Silencing; Immunomodulation; Influenza; Innate Immunity; Nucleic Acids; Pandemic; Protection; Review

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; DEOXYRIBOZYME; NUCLEIC ACID; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; VIRUS RNA;

DRUG EFFECT; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A; METABOLISM; REVIEW; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA, CATALYTIC; GENE EXPRESSION REGULATION, VIRAL; GENE SILENCING; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; NUCLEIC ACIDS; OLIGONUCLEOTIDES, ANTISENSE; RNA, SMALL INTERFERING; RNA, VIRAL; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; VIRUS REPLICATION;

EID: 77957321136     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s102     Document Type: Review

References (72)

1. J. Dushoff, J.B. Plotkin, C. Viboud, D.J. Earn and L. Simonsen: Mortality due to influenza in the United States-An annualized regression approach using multiple-cause mortality data. Am J Epidemiol 163, 181-187 (2006) (Pubitemid 43068987)
2. World Health Organization: http://www.who.int/csr/disease/avian- influenza/country/en/index.html
3. A. Moscona: Oseltamivir resistance - Disabling our influenza defenses. N Eng J Med 353, 2633-2636 (2005) (Pubitemid 41817709)
4. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. A.N. Abdel-Ghafar, T. Chotpitayasunondh, Z. Gao, F.G. Hayden, D.H. Nguyen, M.D. de Jong, A. Naghdaliyev, J.S. Peiris, N. Shindo, S. Soeroso and T.M. Uyeki: Update on avian influenza A (H5N1) infection in humans. N Eng J Med 358, 261-273 (2008)
5. N.J. Dharan, L.V. Gubareva, J.J. Meyer, M. Okomo-Adhiambo, R.C. McClinton, S.A. Marshall, K. St George, S. Epperson, L. Brammer, A.I. Klimov, J.S. Bresee and A.M. Fry: Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301, 1034-1041 (2009)
6. J.P. Wong, M.E. Christopher, A.M. Salazar, R.M. Dale, L.Q. Sun and M. Wang: Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses. Vaccine 25, 3175-3178 (2007) (Pubitemid 46482750)
7. J.P. Wong, M.E. Christopher, S. Viswanathan, N. Karpoff, X. Dai, D. Das, L.Q. Sun, M. Wang and A.M. Salazar: Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine 27, 3481-3483 (2009)
8. E.G. Saravolac, L.Q. Sun, M.J. Cairns and J.P. Wong: Nucleic acid-based drugs as antiviral agents. Recent Devel Antiviral Res 1, 117-141 (2001)
9. M.E. Christopher and J.P. Wong: Recent developments in delivery of nucleic acid-based antiviral agents. Curr Pharm Des 12, 1995-2006 (2006) (Pubitemid 43821688)
10. A.M. Krieg: Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta 1489, 107-116 (1999)
11. H.B. Levy, G. Baer, S. Baron, C.E. Buckler, C.J. Gibbs, M.J. Iadarola, W.T. London and J. Rice: A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis 132, 434-439 (1975)
12. A.M. Krieg: Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 4, 289-294 (2007) (Pubitemid 47036451)
13. G.C. Sen and S.N. Sarkar: Transcriptional signaling by double-stranded RNA: role of TLR3. Cytokine Growth Factor Rev 16, 1-14 (2005) (Pubitemid 40279114)
14. L. Guillot, R. Le Goffic, S. Bloch, N. Escriou, S. Akira, M. Chignard and M. Si-Tahar: Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 280, 5571-5580 (2005) (Pubitemid 40280035)
15. L. Liu, I. Botos, Y. Wang, J.N. Leonard, J. Shiloach, D.M. Segal and D.R. Davies: Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 320, 379-381 (2008) (Pubitemid 351555661)
16. J.P. Wong, E.G. Saravolac, D. Sabuda, H.B. Levy and M. Kende: Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice. Antimicrob Agents Chemother 39, 2574-2576 (1995)
17. J.P. Wong, H. Yang, L. Nagata, M. Kende, H. Levy, G. Schnell and K. Blasetti: Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. Vaccine 17, 1788-1795 (1999) (Pubitemid 29138919)
18. A.M. Krieg, A.K. Yi, S. Matson, T.J. Waldschmidt, G.A. Bishop, R. Teasdale, G.A. Koretzky and D.M. Klinman: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549 (1995)
19. A.M. Krieg: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20, 709-760 (2002) (Pubitemid 34293438)
20. G. Hartmann, G.J. Weiner and A.M. Krieg: CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 96, 9305-9310 (1999) (Pubitemid 29374750)
21. D. Askew, R.S. Chu, A.M. Krieg and C.V. Harding: CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol 165, 6889-6895 (2000) (Pubitemid 32001158)
22. R.S. Chu, O.S. Targoni, A.M. Krieg, P.V. Lehmann and C.V. Harding: CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186, 1623-1631 (1997) (Pubitemid 27506276)
23. B.M. Manning, E.Y. Enioutina, D.M. Visic, A.D. Knudson and R.A. Daynes: CpG DNA functions as an effective adjuvant for the induction of immune responses in aged mice. Exp Gerontol 37, 107-126 (2001) (Pubitemid 33152703)
24. J.P. Wong, L.P. Nagata, M.E. Christopher, A.M. Salazar and R.M. Dale: Prophylaxis of acute respiratory virus infection using nucleic acid-based drugs. Vaccine 23, 2266-2268 (2005) (Pubitemid 40341464)
25. M.E. Christopher and J.P. Wong: Broad-spectrum drugs against antiviral agents. Int J Mol Sci 9, 1561-1594 (2008)
26. A. Alama, F. Barbieri, M. Cagnoli and G. Schettini: Antisense oligonucleotides as therapeutic agents. Pharmacol Res 36, 171-178 (1997) (Pubitemid 27480714)
27. S.T. Crooke: Molecular mechanisms of antisense drugs: RNase H. Antisense Nucleic Acid Drug Dev 8, 133-134 (1998) (Pubitemid 28223333)
28. A. Zerial, N.T. Thuong and C. Hélène: Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent. Nucleic Acids Res 15, 9909-9919 (1987) (Pubitemid 18011709)
29. J.M. Leiter, S. Agrawal, P. Palese and P.C. Zamecnik: Inhibition of influenza virus replication by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci USA 87, 3430-3434 (1990)
30. T. Hatta, Y. Nakagawa, K. Takai, S. Nakada, T. Yokota and H. Takaku: Inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by unmodified, phosphorothioated, and liposomally encapsulated oligonucleotides. Biochem Biophys Res Commun 223, 341-346 (1996) (Pubitemid 26245570)
31. T. Hatta, K. Takai, S. Nakada, T. Yokota and H. Takaku: Specific inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by liposomally endocapsulated antisense phosphorothioate oligonucleotides: penetration and localization of oligonucleotides in clone 76 cells. Biochem Biophys Res Commun 232, 545-549 (1997) (Pubitemid 27216257)
32. T. Mizuta, M. Fujiwara, T. Hatta, T. Abe, N. Miyano-Kurosaki, S. Shigeta, T. Yokota and H. Takaku: Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A. Nat Biotechnol 17, 583-587 (1999) (Pubitemid 29262923)
33. T. Abe, T. Hatta, K. Takai, H. Nakashima, T. Yokota and H. Takaku: Inhibition of influenza virus replication by phosphorothioate and liposomally endocapsulated oligonucleotides. Nucleosides Nucleotides 17, 471-478 (1998) (Pubitemid 28141556)
34. T. Mizuta, M. Fujiwara, T. Abe, N. Miyano-Kurosaki, T. Yokota, S. Shigeta and H. Takaku: Inhibitory effects of an antisense oligonucleotide in an experimentally infected mouse model of influenza A virus. Biochem Biophys Res Commun 279, 158-161 (2000)
35. J.P.H. Wong and L.P. Nagata: Therapy of respiratory influenza virus infection using free and liposome-encapsulated ribonucleotides. US Patent No. 6, 544, 958 (2003)
36. H.M. Moulton, M.H. Nelson, S.A. Hatlevig, M.T. Reddy and P.L. Iversen: Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem 15, 290-299 (2004) (Pubitemid 38365188)
37. A. Amantana and P.L. Iversen: Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr Opin Pharmacol 5, 550-555 (2005) (Pubitemid 41258575)
38. Q. Ge, M. Pastey, D. Kobasa, P. Puthavathana, C. Lupfer, R.K. Bestwick, P.L. Iversen, J. Chen and D.A. Stein: Inhibition of multiple subtypes of influenza A virus in cell cultures with morpholino oligomers. Antimicrob Agents Chemother 50, 3724-3733 (2006) (Pubitemid 44684887)
39. G. Gabriel, A. Nordmann, D.A. Stein, P.L. Iversen and H.D. Klenk: Morpholino oligomers targeting the BP1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7. J Gen Virol 89, 939-948 (2008)
40. C. Lupfer, D.A. Stein, D.V. Mourich, S.E. Tepper, P.L. Iversen and M. Pastey: Inhibition of influenza A H3N8 virus infections in mice by morpholino oligomers. Arch Virol 153, 929-937 (2008)
41. P.C. Haasnoot, D. Cupac and B. Berkhout: Inhibition of virus replication by RNA interference. J Biomed Sci 10, 607-616 (2003)
42. J. Haasnoot and B. Berkhout: Antiviral RNA interference strategies targeting influenza virus and other respiratory viruses. In: Combating the threat of pandemic influenza: drug discovery approaches. Eds: P.F. Torrence. John Wiley & Sons, Inc., Hoboken, NJ. 148-165 (2007)
43. M.J. Cairns: Small interfering RNAs and their therapeutic applications in mitigation of virus replication and pathological effects in the respiratory tract. Anti-Inflammatory & Anti-Allergy Agents in Med Chem 7, 116-121 (2008)
44. R.P. Lyer, A. Roland, W. Zhou and K. Ghosh: Modified oligonucleotides - synthesis, properties and applications. Curr Opin Mol Ther 1, 344-358 (1999) (Pubitemid 29309183)
45. M. Boczkowska, P. Guga and W.J. Stec: Stereodefined phosphorothioate analogues of DNA: relative thermodynamic stability of the model PS-DNA/DNA and PS-DNA/RNA complexes. Biochemistry 41, 12483-12487 (2002)
46. C.M. Liu, Z. Yang, C.W. Liu, R. Wang, P. Tien, R. Dale and L.Q. Sun: Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther 14, 945-952 (2007) (Pubitemid 350115358)
47. C.M. Liu, Z. Yang, C.W. Liu, R. Wang, P. Tien, R. Dale, and L.Q. Sun. Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice. Gene Ther 15, 155-160 (2008) (Pubitemid 351150039)
48. Y. Wu, G. Zhang, Y. Li, Y. Jin, R. Dale, L.Q. Sun and M. Wang: Inhibition of highly pathogenic avian H5N1 influenza virus replication by RNA oligonucleotides targeting NS1 gene. Biochem Biophys Res Commun 365, 369-374 (2008) (Pubitemid 350137299)
49. A. Hampel and R. Tritz: RNA catalytic properties of the minimum (-)s TRSV sequence. Biochemistry 28, 4929-4933 (1989) (Pubitemid 19162737)
50. J. Haseloff and W.L. Gerlach: Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334, 585-591 (1988)
51. L.Q. Sun, M.J. Cairns, E.G. Saravolac, A. Baker and W.L. Gerlach: Catalytic nucleic acids: from lab to applications. Pharmacol Rev 52, 325-347 (2000)
52. R.H. Symons: Ribozymes. Curr Opin Struct Biol 4, 322-330 (1994) (Pubitemid 24195846)
53. P.J. Welch, R. Tritz, S. Yei, J. Barber and M. Yu: Intracellular application of hairpin ribozyme genes against hepatitis B virus. Gene Ther 4, 736-743 (1997) (Pubitemid 27343136)
54. P.J. Welch, R. Tritz, S. Yei, M. Leavitt, M. Yu and J. Barber: A potential therapeutic application of hairpin ribozymes: in vitro and in vivo studies of gene therapy for hepatitis C virus infection. Gene Ther 3, 994-1001 (1996) (Pubitemid 26397474)
55. L.Q. Sun, J. Pyati, J. Smythe, L. Wang, J. Macpherson, W. Gerlach and G. Symonds: Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs. Proc Natl Acad Sci USA 92, 7272-7276 (1995)
56. D.Z. Liu, Y.X. Jin, H. Hou, Y.Z. Huang, G.C. Yang and Q. Xu: Preparation and identification of activity of anti-HPV-6b/11E1 universal ribozyme - Rz1198 in vitro. Asian J Androl 1, 195-201 (1999)
57. X.B. Tang, G. Hobom and D. Luo: Ribozyme mediated destruction of influenza A virus in vitro and in vivo. J Med Virol 42, 385-395 (1994) (Pubitemid 24128135)
58. V.N. Lazarev, M.M. Shmarov, A.N. Zakhartchouk, G.K. Yurov, O.U. Misurina, T.A. Akopian, N.F. Grinenko, N.G. Grodnitskaya, N.V. Kaverin and B.S. Naroditsky: Inhibition of influenza A virus reproduction by a ribozyme targeted against PB1 mRNA. Antiviral Res 42, 47-57 (1999) (Pubitemid 29234148)
59. D. Plehn-Dujowich and S. Altman: Effective inhibition of influenza virus production in cultured cells by external guide sequences and ribonuclease P. Proc Natl Acad Sci USA 95, 7327-7332 (1998) (Pubitemid 28293251)
60. L. Beigelman, J.A. McSwiggen, K.G. Draper, C. Gonzalez, K. Jensen, A.M. Karpeisky, A.S. Modak, J. Matulic-Adamic, A.B. DiRenzo, P. Haeberli, D. Sweedler, D. Tracz, S. Grimm, F.E. Wincott, V.G. Thackray and N. Usman: Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J Biol Chem 270, 25702-25708 (1995)
61. J.P. Desjardins, B.S. Sproat, B. Beijer, M. Blaschke, M. Dunkel, W. Gerdes, J. Ludwig, V. Reither, T. Rupp and P.L. Iverson: Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections. J Pharmacol Exp Ther 278, 1419-1427 (1996) (Pubitemid 27166996)
62. M. Sioud and D.R. Sørensen: A nuclease-resistant protein kinase C alpha ribozyme blocks glioma cell growth. Nat Biotechnol 16, 556-561 (1998) (Pubitemid 28269814)
63. K.G. Draper: Method and reagent for inhibiting influenza virus replication. U.S. Patent No. 6,258,585 (2001)
64. S.W. Santoro and G.F. Joyce: Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry 37, 13330-13342 (1998) (Pubitemid 28449578)
65. S.W. Santoro and G.F. Joyce: A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 94, 4262-4266 (1997) (Pubitemid 27194229)
66. H. Unwalla and A.C. Banerjea: Novel mono- and di-DNA-enzymes targeted to cleave TAT or TAT-REV RNA inhibit HIV-1 gene expression. Antiviral Res 51, 127-139 (2001) (Pubitemid 32592501)
67. B. Sriram and A.C. Banerjea: In vitro-selected RNA cleaving DNA enzymes from a combinatorial library are potent inhibitors of HIV-1 gene expression. Biochem J 352, 667-673 (2000) (Pubitemid 32015021)
68. X. Zhang, Y. Xu, H. Ling and T. Hattori: Inhibition of infection of incoming HIV-1 virus by RNA-cleaving DNA enzyme. FEBS Lett 458, 151-156 (1999) (Pubitemid 29428173)
69. R. Goila, and A.C. Banerjea: Inhibition of hepatitis B virus X gene expression by novel DNA enzymes. Biochem J 353, 701-708 (2001) (Pubitemid 32158339)
70. M. Oketani, Y. Asahina, C.H. Wu and G.Y. Wu: Inhibition of hepatitis C virus-directed gene expression by a DNA ribonuclease. J Hepatol 31, 628-634 (1999) (Pubitemid 29487683)
71. T. Toyoda, Y. Imamura, H. Takaku, T. Kashiwagi, K. Hara, J. Iwahashi, Y. Ohtsu, N. Tsumura, H. Kato and N. Hamada: Inhibition of influenza virus replication in cultured cells by RNA-cleaving DNA enzyme. FEBS Lett 481, 113-116 (2000)
72. M.J. Cairns, T.M. Hopkins, C. Witherington, L. Wang and L.Q. Sun: Target site select ion for an RNA-cleaving catalytic DNA. Nat Biotechnol 17, 480-486 (1999). (Pubitemid 29217902)